Objective: The evaluation of peripheral vascular disease in the primary care setting is routinely performed by contrast-enhanced magnetic resonance angiography (CE-MRA) and digital subtraction angiography (DSA). However, limited data are available on the relative costs and clinical outcomes following these diagnostic procedures. The objective of this study is to assess and compare costs associated with diagnostic imaging in peripheral vascular occlusive disease (PAOD). Methods: US veterans (n = 19,209) with CE-MRA or DSA for the assessment of PAOD from fiscal year (FY) 1999 to FY 2004. Main outcome measure(s) using the Department of Veterans Affairs' (VA) costing algorithms, cost, and log-cost of interventions (e.g., revascularization, stent, angioplasty), amputations or mortality rates within 30/90 days and 1 year of DSA or CE-MRA were compared, and adjusted for patient characteristics and disease severity using multivariate regression. Imaging modality selection bias was evaluated with propensity score, instrumental variables, and Heckman methods using untransformed costs and log-costs with smearing retransformation. Results: Initial CE-MRA imaging was significantly more likely among patients with prior renal disease or bypass surgery [odds ratio (OR) > 2; P < 0.001], and less likely among patients with prior amputation, peripheral vascular disease (PVD), claudication, or other cardiovascular disease (OR < 0.7; P < 0.001). After adjusting for endogenous choice of initial imaging modality, 30-day treatment costs were US$3500-$4300 lower (P < 0.001) for patients with initial CE-MRA. Eighty-two percent of DSA imaging patients had no additional procedures or events within 30 days, and 65% at 90 days. Less than 3.2% (3.6%) of patients had any repeat imaging within 30 (90) days of initial imaging. Conclusions: Relative to DSA, CE-MRA imaging was associated with substantial treatment episode savings, beyond the US$950 direct savings in imaging cost per procedure. Substituting CE-MRA for DSA among those not planning or requiring any follow-up procedures within 30 days, could have reduced outpatient imaging costs by up to 55%, and reduced VA system costs by US$13.2 million over the six-year period.
Introduction
In 2005, approximately 80 million advanced diagnostic radiology exams were conducted in the United States. The cost for these tests was approximately US$100 billion, up from about $75 billion in 2000 [1] . Diagnostic imaging services have shown the highest cumulative rate of growth of all Medicare services over the 1999-2003 period [2] . Of these diagnostic imaging services, Magnetic Resonance Imaging (MRI) for body sites other than the brain had the highest rate of growth of all Medicare imaging procedures. Nevertheless, MRI has the smallest share of the imaging market. In 2002, MRI scans accounted for only 6.5% of total US imaging procedures and are projected to rise to 12% in 2008 [3] .
Angiography uses one of three imaging technologies and, in some cases, a contrast material to image the major blood vessels throughout the body. Angiography is performed using: 1) an invasive procedure-x-rays with catheters (digital subtraction angiography or DSA); 2) computed tomography (CT); or 3) MRI. In magnetic resonance angiography (MRA), magnetic field, radio waves, and a computer produce the detailed images. MRA is noninvasive and does not use ionizing radiation (x-rays). MRA may be performed with or without contrast material.
Despite the rapid and expensive growth in imaging services, there are few published cost effectiveness analyses regarding the use of these services, and there is little information on the impact of alternative diagnostic imaging modalities on patient clinical outcomes or costs. Most of the existing literature on MRA versus DSA is based on relatively small patient samples and short-term follow-up, with modeling techniques used to evaluate more long-term costs and outcomes [4, 5] . The American College of Radiology has developed appropriateness criteria for a number of common presentations, and recommendations for tests that have been found to be particularly effective and tests that are not as effective. Nevertheless, third party payers have not generally incorporated such evidence-based medicine criteria into reimbursement policies [6] .
One example of the growing use of imaging is in the evaluation of patients presenting with suspected peripheral artery occlusive disease (PAOD). Studies assessing the cost effectiveness of both contrast-enhanced MRA (CE-MRA) and DSA, are limited in nature and are generally based on small clinical studies to evaluate the imaging precision of either testing strategy [7] [8] [9] . These studies have generally shown MRA to be cost effective relative to DSA. However, there is little evidence linking the clinical impact of either modality as a screening procedure to guide treatment interventions among patients with PAOD. Visser et al. [7] found that MRA is cost effective compared with DSA for less invasive surgery patients, but DSA is cost effective compared with MRA for invasive surgery patients. However, qualityadjusted life-year differences (0.0011 less invasive; 0.0118 invasive) and the cost differences ($690 less invasive; $229 invasive) were quite small. We are not aware of any studies that have evaluated cost differences between these imaging procedures in large multiyear patient populations.
This study aims to evaluate medical treatment costs associated with the patterns of diagnostic imaging of the lower extremity for patients initiating either DSA or CE-MRA in the ambulatory care sector. The study evaluates the relative costs of complications because of imaging with each diagnostic modality, and the treatment costs for lower extremity interventions following imaging. FY2005) . All subjects of the cohort used the Veterans Administration Healthcare system between the years FY1999 and FY2005. To ensure that we had at least one year's follow-up from the index date of diagnosis, we only included patients with an initial diagnosis date during or before FY2004. We excluded 1134 subjects from the original dataset because they did not have one year's follow-up after the primary lower extremity imaging procedure.
Methods

Data Sources
To describe the patterns of lower extremity imaging procedures for the diagnosis of PAOD, we categorized the cohort into two groups based on the primary imaging procedure, either MRA or DSA. We required patients to have 12 months of VA utilization without history of MRA prior to any incident MRA, to identify "new" imaging procedures courses of care. We also required 12 months of follow-up postimaging, to better assess any potential complications, to ensure the patient was not transferred out of the system postimaging. The Charlson comorbidity index is time sensitive, and we used a 365-day look-back incorporating both inpatient and outpatient diagnostic and procedure data to ensure that we obtained complete capture of Charlson criteria, and did not engineer any bias because of a differential follow-up in the system. Disease covariates were identified using a minimum of 12 months of follow-up; however, we used the breadth of the database to characterize duration of chronic disease conditions of interest. Sensitivity analyses using 12-month windows of look-back do not produce meaningful differences in disease estimates versus using longer windows.
PAOD Treatment Event Costs
The primary outcomes of interest in this study were medical costs associated with lower extremity revascularization or surgical interventions, repeat imaging procedures, complications within 30 days, and death following imaging procedure. Comparison of differences in practice patterns, and clinical outcomes associated with the two imaging modalities are described elsewhere [10] .
Interventions 
Patient Demographic and Medical History Covariates
With regard to practice pattern differences, we measured baseline characteristics such as baseline age, race, and gender along with information on the following disease covariates: diabetes mellitus (ICD-9 code: 250-250.9), hypertension (ICD-9 code: 401, 401.01, 401.1, 401.9), cardiovascular disease (ICD-9 codes: 00.66, 36, 410-414), baseline peripheral vascular disease (ICD-9 code: 443.9), chronic renal disease (ICD-9 code: 585.9), atherosclerosis of extremities with intermittent claudication (ICD-9 code: 440.21), and baseline revascularization or surgical interventions for peripheral vascular disease (PTA or stent or bypass or amputation; ICD-9 codes specified earlier). We also captured baseline Charlson comorbidity index scores for sample patients [11] .
Cost Measurement
We used VA average costs per procedure to assess the medical care costs associated with imaging modalities and the follow-on procedures identified above. We excluded costs for treatment of comorbidities or other medical events that were clearly unrelated to the initial imaging procedure. We used US dollar costs from the national VA data for FY2004 because it was the most current year available with complete prices and because there was nothing indicating that the 2003 estimates were a better basis for our cost estimates (e.g., procedure frequencies were not greater in 2003, the variation in costs was not less, combining the 2 years did not reduce variation, etc.).
Data Analysis
Initial imaging modality selection is subject to endogenous treatment selection bias [12] . Patients presenting with the highest PAOD symptom severity levels would be more likely to receive DSA rather than CE-MRA because this would allow the treating physician to initiate an immediate or emergency vascular procedure if necessary. Similarly, patients presenting with renal disease would be more likely to receive CE-MRA because the DSA imaging contrast agents are more likely to lead to complications in renal patients. It was clear from the evaluation of the descriptive statistics regarding patient demographics and medical histories that there were substantial differences in patient characteristics between those patients choosing CE-MRA or DSA as the initial outpatient imaging modality [10] . In order to adjust for both observable and unobservable characteristics that could confound and bias the effect of initial imaging modality on treatment cost differences, we used the Heckman selection bias and instrumental variables estimates of the CE-MRA and DSA cost differences, as well as simple OLS multivariate regression estimates with and without propensity score adjustments [12] . Because we didn't have any explanatory variables that were plausible instruments themselves (i.e., that could plausibly be excluded from the cost equation but not from the treatment choice equation), we used the fitted propensity score as an instrument for the endogenous binary treatment choice variable [CE-MRA vs. DSA as the initial diagnostic procedure]. The propensity score method and the Heckman selection bias methods involved adding, respectively, the additional regressors pi (the fitted propensity score from Table 2 ) and -fi/pi (the fitted inverse Mills ratio based on the probit treatment selection equation (available from the authors upon request). For the instrumental variables estimates, the fitted propensity scores and inverse Mills ratios are included as instruments for the endogenous treatment selection variable. We also ran models using log-transformed costs with Smearing estimates of the standard errors for retransformation as a robustness check on the untransformed cost regression models.
Results
Patient Descriptive Statistics
In the years 1999 through 2005, 19,209 patients underwent an initial diagnostic imaging procedure at a VA facility. Of these patients, 3183 underwent MRA as the first imaging procedure and 16,026 underwent DSA as the first imaging procedure. Table 1 describes the differences between the MRA and DSA groups in baseline characteristics.
The proportion of patients undergoing a second imaging procedure within 1 year was low (CE-MRA, 9.6%; DSA, 6.6%). The proportion with repeat imaging 30 days/90 days after the initial diagnostic procedure was very low (CE-MRA, 3.1% 30-day/5.5% 90-day; DSA, 1.3% 30-day/2.5% 90-day). The percentage of patients with any additional procedures or events within 30 days/90 days was also low (CE-MRA, 8% 30-day/ 24% 90-day; DSA, 18% 30-day/35% 90-day). 
Imaging Procedure Costs
The average unadjusted FY2004 cost in the VA system for a CE-MRA imaging procedure was $470, although the average unadjusted cost for a DSA imaging procedure was $1420, for a net savings with an initial CE-MRA imaging procedure of $950. The multivariate econometric analysis was utilized to determine if 30-or 90-day treatment costs or complication costs were significantly different after adjusting for potential endogenous choice of imaging modality, as described below.
Imaging Complications
As reported elsewhere [10] , there were no statistically significant differences in mortality rates or in treatment complication rates between the two initial diagnostic modalities with the exception of hematoma rates (30-day rates: CE-MRA, 0.4%; DSA, 1.8%; P < 0.0001). Because the average cost of treating a hematoma is generally less than $9000 [13] , this would add a maximum of $90 to the average cost of patients initially imaged with DSA. However, using patient baseline characteristics and propensity score adjustments as additional explanatory factors in a logistic regression of vascular complication rates on initial imaging modality showed that after adjusting for these factors, the rate of vascular complications was not statistically significant between the two initial imaging modalities. Therefore, we conservatively ignored treatment complication costs in assessing our estimates of the 30-day and 90-day cost differences between CE-MRA and DSA.
Imaging Modality Selection and Follow-up Procedure Cost Differences between CE-MRA and DSA Patients
Initial CE-MRA imaging was significantly more likely among patients with prior renal disease or bypass surgery [odds ratio (OR) > 1.99; P < 0.001], and less likely among patients with prior amputation, PVD, claudication, or other cardiovascular disease markers except for congestive heart failure (CHF) (OR < 0.7; P < 0.001) (see Table 2 ). Table 3 presents the propensity score-adjusted medical treatment costs for 30 days and 90 days, after the initial imaging procedure for CE-MRA and DSA patients. They show that patient treatment costs were $3920 (30-day) and $5209 (90-day) lower for CE-MRA patients than DSA patients, even after adjusting for choice of imaging modality and other patient characteristics (P < 0.0001). Using alternative methods for adjusting for endogenous choice of initial imaging modality, 30-day treatment costs were $3300-$4300 lower (P < 0.001) for imaging patients with initial CE-MRA, depending on whether propensity scores, Heckman selection bias coefficients, or instrumental variables were used to correct for endogenous selection bias (see Table 4 ). The results were robust to whether costs, log-costs, or other power transformations of the dependent cost variable were utilized in the regressions.
Discussion
In this retrospective study of almost 20,000 VA patients undergoing outpatient diagnostic imaging of the lower extremity, the rates of follow-up imaging procedures and follow-up medical or surgical procedures within 30 or 90 days of the initial CE-MRA or DSA was quite low. Complications following either of the two diagnostic imaging methods were rare and not statistically different after adjustment for selection bias. Even if we were to ascribe a 1% greater occurrence of hematomas complication rates to DSA, this would only increase our estimate of the cost savings associated with CE-MRA by a maximum of $90 per patient. There was also no statistically significant difference in mortality rates between the two imaging groups. Relative to DSA, CE-MRA imaging was associated with substantial treatment episode health care savings, beyond the $950 direct savings in imaging cost per initial procedure. These savings estimates were robust to alternate model specifications and statistical corrections for endogenous selection of imaging modality. Even setting aside the higher 30-and 90-day follow-up costs for DSA patients, substituting CE-MRA for DSA among the 82% of DSA patients not planning or requiring any follow-up procedures within 30 days could have reduced outpatient imaging costs by 55%, and reduced VA system costs by $13.2 million ($950 savings per imaging procedure multiplied by 82% of the 16,961 DSA patients) over the six-year period. There was no evidence in these data that there would be any offsetting clinical or cost disadvantages for substituting CE-MRA among those patients not anticipating any additional medical procedures within 30 days of the initial outpatient diagnostic imaging.
It is unclear why DSA patients used more procedures and interventions than CE-MRA patients subsequent to the initial outpatient imaging procedure, even after adjusting for patient characteristics and imaging selection bias. It is possible that some residual patient selection bias remains, with higher severity patients receiving initial DSA rather than CE-MRA, but patients with the highest level of severity are unlikely to receive additional procedures because most interventions are ineffective in patients with extreme peripheral artery occlusions.
Studies comparing outcomes following either MRA or DSA in the evaluation of PAOD are lacking. Studies assessing the accuracy of both tests have concluded that both testing modalities are comparable regarding the severity and location of the atherosclerotic lesions [14] . Hematoma, arterial wall dissection, and thrombosis, are reported to occur up to 7.3% following DSA [15] .
Our analysis is also limited by the retrospective nature of the medical service utilization data that we were able to analyze. We undertook a substantial medical chart review to ensure that our ICD-9 and procedure code nets for diagnoses, follow-on procedures, complications, etc., were valid and reliable. Nevertheless, there is always some possibility that patients may have received some relevant medical care services in non-VA facilities. Moreover, the VA patient population is atypical in terms of several patient demographic characteristics and provider incentives. Nevertheless, we suspect that any cost differences that we have identified are at least as likely to be found in other patient populations.
This study finds that there is substantial cost savings associated with the use of CE-MRA, relative to DSA as initial outpatient imaging modality for PAOD patients. Although we were able to identify substantial systematic differences in demographic and medical history characteristics between patients receiving CE-MRA and DSA, large majorities of both patient groups received no follow-on medical procedures within 30 or 90 days, suggesting that substantial cost savings could be realized with the less-expensive CE-MRA imaging procedure. Moreover, it appears as though treatment costs for patients initiating CE-MRA imaging procedures are $3000-$5000 less than patients initiating DSA imaging procedures, even after an adjustment for available potential confounders and treatment selection bias. These cost savings are substantially greater than those reported in the literature [4, 5, [7] [8] [9] .
